Explore the Agenda
7:30 am Check In, Coffee & Light Breakfast
8:25 am Chair’s Opening Remarks
Differentiating Next-Generation Therapies Through Novel Pathways, Precision Targeting & Improved Durability
8:30 am Panel Discussion: Targeting Novel Pathways Beyond IL & JAK Inhibitors to Differentiate Therapies & Expand Treatment Options
- Exploring novel biological pathways beyond established mechanisms, unlocking new therapeutic angles, to differentiate pipelines in a crowded market
- Validating emerging targets with translational data, reducing scientific uncertainty, to increase success rates in development
- Expanding modality and pathway diversity, broadening treatment options, to address unmet patient needs
9:00 am Session Reserved for SCARLETRED
9:30 am Panel Discussion: Competing Beyond Dupixent: Leveraging Unique Mechanisms of Action & Long- Acting Drugs to Differentiate in the Next Wave of Atopic Dermatitis Therapeutics
- Positioning new mechanisms of action such as IL-31 inhibition and long-acting drugs as a potentially best-in-class alternative in moderate-to-severe atopic dermatitis
- Assessing how infrequent maintenance dosing compares with Dupixent, Ebglyss and oral JAK inhibitors, improving convenience and long-term adherence potential, to strengthen differentiation in an increasingly crowded AD market
- Understanding whether deeper and sustained responses with highly selective IL-13 blockade can redefine competitive benchmarks for efficacy, safety and patient preference, aligning clinical outcomes with payer and physician expectations, to maximise uptake and commercial value ahead of planned Phase 3 initiation in 2H 2026
10:00 am Speed Networking
A prime chance to make the most of in-person networking and forge new connections as new companies enter and existing ones broaden their presence within the dermatology space. This is designed to maximize your exposure to a wide range of new individuals and serve as a catalyst for ongoing discussions throughout the summit.
10:45 am Morning Break & Refreshments
Discovering the Next Generation of Dermatology Targets:
Leveraging Novel Biology, Translational Science & Precision Immunology to De-Risk Innovation
Strengthening Translational Confidence in Dermatology: Building More Predictive Models & Learning from Clinical Outcomes to Improve Discovery Decisions
11:00 am Building Predictive Human-Relevant Skin Models to Improve Translational Confidence & Accelerate First-in- Human Readiness
- Developing ex vivo, in vitro and chip-based skin models, improving human relevance, to strengthen confidence before clinical translation
- Testing emerging modalities in engineered model systems, capturing delivery, target engagement and tissue response, to reduce uncertainty before dose selection
- Learning from model innovation to benchmark advanced platform approaches, and improve preclinical decision-making across difficult dermatology questions
11:30 am Roundtable Discussion: Back-Translating Clinical Readouts into Discovery Workflows to Improve Model Relevance & Target Selection
- Interpreting clinical failures and efficacy ceilings in HS, AD and psoriasis, revealing which preclinical assumptions did or did not translate, to refine future target validation strategies
- Connecting patient pathology with animal, in vitro and tissuebased models, clarifying what each model truly represents, to avoid overinterpreting contrived systems
- Applying learnings from IL-17, IL-23, TNF, IL-1, JAK and OX40L programs, identifying pathway-specific translational gaps, to prioritise more clinically relevant discovery work
Redefining Topical Dermatology: Advancing Novel Mechanisms &
Clinical Strategies to Deliver Meaningful Differentiation in Acne &
Alopecia Areata
Optimizing Therapeutic Performance in Dermatology: Advancing Dosing, Delivery & Multi-Mechanistic Approaches to Maximize Clinical Impact
11:00 am Optimizing Dosing Strategies to Enhance Efficacy & Differentiate Dermatology Therapies
- Explain how model-informed drug development (MIDD) approaches, integrating clinical data and quantitative pharmacology methodologies, were applied to support dose selection for nemolizumab in 2 different indications
- Demonstrate the role of body weight as a key intrinsic covariate influencing the PK profile of nemolizumab, and how this finding informed the implementation of a body weight–
- tiered dosing strategy in Prurigo Nodularis versus a fixed dosing regimen in Atopic Dermatitis
11:30 am Moving Beyond Single-Target Therapies: Clinical Development Insights from a Multi-Target Platform in Atopic Dermatitis & Molluscum Contagiosum
- Exploring how multi-mechanistic therapeutics may address complex disease biology more effectively than conventional single-target approaches
- Reviewing pharmacokinetic, mechanistic and translational learnings supporting development across inflammatory and infectious dermatological conditions
- Discussing Phase 2 clinical development strategies and crossindication insights to accelerate future applications of multitarget therapeutics
12:00 pm Advancing Delivery Systems to Improve Patient Experience & Enhance Therapeutic Impact
- Exploring innovative delivery systems, improving usability, to increase patient adherence
- Enhancing drug delivery performance to maximize efficacy and improve outcomes
- Differentiating therapies through formulation, strengthening positioning, to gain competitive advantage
12:00 pm Lunch & Networking Break
Discovering the Next Generation of Dermatology Targets:
Leveraging Novel Biology, Translational Science & Precision
Immunology to De-Risk Innovation
1:30 pm Targeting Inflammation at the Source: Advancing ENGI-004 to Deliver Tissue-Selective Immune Modulation in Atopic Dermatitis
- Exploring a novel tissue-targeted approach to immunomodulation by engaging MHC-related receptors enriched at barrier tissues, including the skin, to concentrate activity where disease occurs
- Leveraging AI-guided protein engineering to optimize efficacy and safety through precise delivery of inhibitory signals to inflamed tissues while minimizing systemic immune suppression
- Translating ENGI-004 from discovery toward clinical development to establish a differentiated therapeutic strategy for atopic dermatitis and other barrier tissue inflammatory diseases
2:00 pm From Ocean Biology to Dermatology Therapeutics: Using Translational Science to Identify Biomarkers, Validate Targets & Accelerate Drug Discovery
- Applying translational medicine approaches to uncover novel biomarkers and therapeutic pathways, transforming biological observations into validated targets for inflammatory skin disease
- Exploring how mechanistic insights into oxidative stress, immune regulation and tissue homeostasis can strengthen target selection, increasing confidence in emerging pathways such as AHR before clinical development
- Sharing lessons from translating novel biological discoveries into dermatology drug candidates, demonstrating how early biomarker characterization can reduce development risk and improve the probability of clinical success
Redefining Topical Dermatology: Advancing Novel Mechanisms &
Clinical Strategies to Deliver Meaningful Differentiation in Acne &
Alopecia Areata
1:30 pm Raising the Bar in Alopecia Areata: Positioning Next- Generation Topical Therapies to Deliver Meaningful Hair Regrowth in a JAK-Dominated Market
- Examining why previous topical approaches have struggled in alopecia areata, identifying key biological, formulation and clinical development challenges, to inform the next generation of topical therapies
- Defining meaningful clinical differentiation beyond oral JAK inhibitors, evaluating efficacy, durability, safety and patient preference considerations, to establish where topical therapies can create value in an increasingly competitive treatment landscape
- Optimizing clinical trial design and endpoint selection for topical agents, addressing unique development challenges around efficacy assessment, patient selection and long-term treatment expectations, to improve the likelihood of clinical and regulatory success
2:00 pm Phase III-Ready Topical PPARy Modulator for Moderateto- Severe Acne
- Novel first-in-class topical PPARy modulator designed to target multiple acne pathways simultaneously, including inflammation, sebogenesis and keratinocyte dysfunction
- Phase IIb study in 450 patients demonstrated significant reductions in total lesion count and improved Investigator Global Assessment (IGA) success rates with a favourable safety and tolerability profile
- Phase III-ready programme with FDA and EMA-aligned development plans, positioning NAC-GED-0507 as a potential first new mechanistically differentiated topical acne therapy in decades
2:30 pm Afternoon Break & Refreshments
Accelerating Dermatology Innovation: Leveraging AI, Precision Medicine & Smarter Development Strategies to Build More Competitive Pipelines
3:00 pm Redefining the Oral Psoriasis Market: Positioning Next-Generation TYK2 Inhibitors to Compete with Biologics on Efficacy, Convenience & Durability
- Demonstrating biologic-like PASI 90 and PASI 100 responses from a once-daily oral TYK2 inhibitor, to position next-generation oral therapies against injectable standards of care
- Assessing rapidity, durability and complete skin clearance outcomes across TYK2 programs, clarifying what level of efficacy is now required for differentiation in psoriasis, to strengthen competitive positioning in an increasingly crowded inflammatory dermatology market
- Understanding how regulators, physicians and payers may evaluate highly selective oral TYK2 inhibition versus established biologics and oral competitors such as Otezla and Sotyktu, aligning clinical development with commercial expectations, to maximize uptake, reimbursement and long-term franchise value
3:30 pm Session Reserved for Quantifcare
3:45 pm From 140 Million Cells to Human Trials: Applying AI & Human Tissue Biology to Accelerate Dermatology Drug Discovery
- Building proprietary cellular atlases through advanced multi-omics approaches to reveal novel disease mechanisms and therapeutic opportunities
- Leveraging AI and machine learning to identify, prioritize and validate targets emerging from complex human biology datasets
- Sharing lessons from advancing an AI-discovered therapeutic from target identification to clinical studies in approximately half the traditional development timeline
4:15 pm Session Reserved for Legit Health
4:25 pm Accelerating Time to Proof-of-Concept to De-Risk Dermatology Pipelines & Unlock Faster Decision-Making
- Reducing time to proof-of-concept through optimized early study design, enabling faster signal detection, to accelerate go/no-go decisions and reduce R&D spend
- Identifying tools to detect early efficacy signals in large patient cohorts, improving trial efficiency, to minimize costly late-stage failures
- Streamlining development pathways for systemic and early-stage assets, enhancing operational speed, to bring therapies to patients faster
4:55 pm Chair’s Closing Remarks
5:00 pm Scientific Poster Session
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of immunology experts eager to hear the latest discoveries in dermatology therapeutic research, you will have the opportunity to display a poster presenting your own work and innovations. Don’t miss out on the chance to connect, learn, and
present.